The content on this site is intended for healthcare professionals only
Dr Harry Erba presents data from the the QuANTUM-First international, randomised, double-blind, placebo-controlled phase 3 study during a press conference at the EHA 2022 meeting.
The study sought to determine whether the addition of quizartinib to standard induction and post-remission consolidation therapy followed by single-agent continuation of quizartinib for up to three years improved overall survival in patients with newly diagnosed FLT3-ITD positive AML.
Watch our interview with Dr Erba here
Read the news story here
Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL
New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Revolutionising myeloma treatment through immune profiling
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Multiple myeloma in a resource constrained setting
